Spots Global Cancer Trial Database for A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
Official Title: An Open-label Study of the Effect of Intermittent Xeloda in Combination With Irinotecan on Treatment Response in Patients With Advanced and/or Metastatic Colorectal Cancer
Study ID: NCT00048139
Conditions
Study Description
Brief Summary: This study will assess the efficacy and safety of intermittent oral Xeloda administration in combination with irinotecan as a first-line treatment in patients with advanced and/or metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months and the target sample size is \<100 individuals.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Phoenix, Arizona, United States
, Fountain Valley, California, United States
, La Jolla, California, United States
, Santa Rosa, California, United States
, Denver, Colorado, United States
, Hutchinson, Kansas, United States
, Las Vegas, Nevada, United States
, Albuquerque, New Mexico, United States
, Albuquerque, New Mexico, United States
, Buffalo, New York, United States
, Houston, Texas, United States
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
